The Medical Letter on Drugs and Therapeutics
In Brief: Stopping Long-Acting Beta-2 Agonists
Download PDF:   US English
Med Lett Drugs Ther. 2010 Mar 22;52(1334):21
 Select a term to see related articles  2010   Advair   Advair Diskus   Advair HFA   Advair Inhalation Aerosol   asthma   beta-2 agonists   Beta-2 agonists for asthma   beta2 agonists   budesonide   Budesonide/formoterol   corticosteroids   Corticosteroids inhaled   Death with long-acting beta-2 agonists   Death with long-acting beta2 agonists   Drugs for Asthma   Flovent diskus   flovent HFA   Fluticasone propionate   Fluticasone/salmeterol   Foradil   formoterol   In brief   In Brief: Stopping Long-Acting Beta-2 Agonists   inhaled   inhaled corticosteroids   Inhaled corticosteroids for asthma   inhaler   inhalers   Issue 1334   LABA   Long-acting beta-2 agonist   Long-acting beta2 agonists   March 22   Oxeze   page 21   Pulmicort   Pulmicort Flexhaler   Pulmicort Turbuhaler   Risk of death with long-acting beta-2 agonists   Risk of death with long-acting beta2 agonists   Salmeterol   Serevent   Stopping Long-Acting Beta-2 Agonists   Symbicort   Symbicort HFA   Symbicort Turbuhaler   volume 52 

A little more than a year ago, The Medical Letter reported the results of an FDA meta-analysis which found that use of a long-acting beta-2 agonist (LABA) such as salmeterol (Severent) or formoterol (Foradil) in patients with asthma was associated with an increased risk of a composite endpoint of asthma-related death, intubation or hospitalization; the highest risk was in children 4-11 years old.There was no significant increase in risk when a long-acting beta-2 agonist was used with an inhaled corticosteroid.The Medical Letter recommended that long-acting beta-2 agonists should not be used as monotherapy for asthma, especially in children, and that long-acting beta-2 agonists should be used for asthma only in combination with an inhaled corticosteroid, preferably in a fixed-dose combination in the same inhaler.1

Now the FDA has issued new Safe Use Requirements2 and labeling requirements for long-acting beta-2 agonists that include the following: “Stop use of the LABA, if possible, once asthma control is achieved and maintain the use of an asthma-controller medication such as an inhaled corticosteroid.”3

It has not been determined that patients taking a long-acting beta-2 agonist in a fixed-dose combination with an inhaled corticosteroid have an increased risk of death or that stopping long-acting beta-2 agonists in such patients will improve long-term outcomes. A controlled clinical trial of these new requirements would be welcome.

1. Long-acting beta-2 agonists in asthma. Med Lett Drugs Ther 2009; 51:1.


3. BA Chowdhury and G Dal Pan. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; Feb 24 (epub).

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article